Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

Ertz-Archambault, Natalie; Kosiorek, Heidi E.; Taylor, Gretchen; Kelemen, Katalin; Dueck, Amylou C.; Castro, Janna C.; Marino, Robert; Gauthier, Susanne M.; Finn, Laura; Sproat, Lisa Z.; Palmer, Jeanne; Mesa, Ruben A.; Al‐Kali, Aref; Foran, James M.; Tibes, Raoul

doi:10.1001/jamaoncol.2016.6435

Cited by 98 publications

(66 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study showed that patients under treatment with anti-TNF agents do not have an increased risk for MDS. 25 Detailed literature search did not reveal any association between 5q deletion and methotrexate or TNF-a inhibitors. Finally, despite the fact that the presence of RA and MDS in the same patient could be an incidental co-existence, further investigation might elucidate the possible role of B cells in RA-associated MDS.…”

Section: Discussionmentioning

confidence: 97%

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report

Evangelatos

Vlachadami

Kechagia

et al. 2017

MJR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report

Evangelatos

Vlachadami

Kechagia

et al. 2017

MJR

View full text Add to dashboard Cite

“…NLR is a recognized tool for the assessment of the systemic inflammatory response and has been shown to be affected by VD [25]. Of clinical relevance is the association between MDS and autoimmune disorders that have been reported in several case report studies and long-term follow-up studies [26,27]. Furthermore, two recent epidemiological studies showed that history of infection was significantly associated with a higher risk of developing MDS [27,28].…”

Section: Discussionmentioning

confidence: 99%

Serum Vitamin D Levels in Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Analysis

et al. 2019

View full text Add to dashboard Cite

Background/Aims: There is growing evidence supporting the role of innate immune deregulation and inflammation in the pathogenesis of myelodysplastic syndromes (MDS). Vitamin D (VD) is known to be involved in various immune and epigenetic processes. This analysis aimed to evaluate serum VD levels in patients with MDS and to analyze associations between serum VD levels and disease characteristics. Methods: Serum levels of 25-hydroxyvitamin D3 (25(OH)-D3), the major form of VD in human serum, were measured by chemiluminescence immunoassay in 62 unselected patients with MDS. Associations between serum 25(OH)-D3 levels and disease characteristics were analyzed using Kendall's tau and two-sided p values. Results: The median serum 25(OH)-D3 level was markedly reduced (17.5 ng/mL). Patients with lower-risk disease features had lower serum 25(OH)-D3 levels than patients with higher-risk disease features with regard to medullary blast counts (16 vs. 31 ng/mL, p < 0.001), the revised international prognostic scoring system (13 vs. 30.5 ng/mL, p = 0.001), and blood counts. Conclusions: We show that patients with lower-risk disease characteristics exhibit lower serum VD levels than patients with higher-risk disease characteristics. Whether these findings might reflect innate immune deregulation has to be investigated in further studies.

show abstract

“…Azathioprine sodium use was observed more frequently in cases, with a 7‐fold risk for myeloid neoplasm. No significant association between a specific length of time of exposure to an agent and the drug's category was observed …”

Section: Registry Studiesmentioning

confidence: 95%

“…A total of 57 out of 86 cases (66.3%) received a cytotoxic or an immunomodulating agent.Azathioprine sodium use was observed more frequently in cases, with a 7-fold risk for myeloid neoplasm. No significant association between a specific length of time of exposure to an agent and the drug's category was observed 105. RESPONSE OF AUTOIMMUNE MANIFESTATIONS TO THERAPIES FOR MDSThe biological interplay existing between the MDS pathogenesis and the development of autoimmune manifestations is somehow mirrored…”

mentioning

confidence: 99%

The burden of autoimmunity in myelodysplastic syndromes

Fozza

2017

Hematological Oncology

View full text Add to dashboard Cite

The clinical history of patients with myelodysplastic syndromes (MDS) is characterised by bone marrow insufficiency as well as by the possible evolution into acute leukaemia. However a number of reports highlight the frequent occurrence of autoimmune manifestations involving different sites and organs. The present review will first describe the clinical pictures most often observed in MDS patients. The actual burden of autoimmunity will be then addressed by focusing on the few available registry studies. Finally, the potential collateral impact of specific treatments for MDS on the evolution of autoimmune disorders will be considered.

show abstract

Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

Cited by 98 publications

References 28 publications

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report

Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report

Serum Vitamin D Levels in Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Analysis

The burden of autoimmunity in myelodysplastic syndromes

Contact Info

Product

Resources

About